Published in Clin Exp Immunol on December 01, 2002
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24
Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun (2012) 1.05
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol (2015) 0.92
Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. Clin Vaccine Immunol (2009) 0.88
Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol (2002) 0.85
Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol (1979) 5.55
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol (1973) 3.77
An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol (1966) 3.72
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med (1988) 3.39
Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol (1979) 3.37
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol (1993) 2.92
Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol (1984) 2.57
The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis (1978) 2.32
Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol (1992) 2.25
Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis (1982) 2.17
Respiratory syncytial virus. I. Concentration and purification of the infectious virus. Acta Med Okayama (1978) 2.01
Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection. Infect Immun (1979) 1.70
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci U S A (1992) 1.54
Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. Prog Med Virol (1980) 1.51
Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis (1992) 1.27
Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis (2000) 1.06
Monoclonal antibodies to the large glycoproteins of respiratory syncytial virus: possible evidence for several functional antigenic sites. J Gen Virol (1987) 1.02
Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus. Clin Exp Immunol (1985) 0.95
Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. J Virol (1991) 0.93
Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants. J Gen Virol (1989) 0.91
Induction of the mucosal immune response. Rev Infect Dis (1988) 0.90
Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol (2000) 0.88
Preventive and therapeutic strategies for respiratory syncytial virus infection. Curr Opin Pharmacol (2001) 0.85
The immunobiology of respiratory syncytial virus: prospects for a vaccine. Adv Exp Med Biol (1989) 0.81
Immunoprophylaxis of respiratory syncytial virus disease. Pediatr Infect Dis J (2000) 0.77
Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J (2000) 0.77
Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A (1996) 12.92
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation (2000) 6.96
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science (1989) 5.73
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science (2001) 5.39
Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation (2000) 5.36
HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (1991) 5.34
Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature (1994) 5.17
Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation (2001) 4.82
Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science (1997) 4.62
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer (2006) 4.46
A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res (1989) 4.29
Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A (1996) 3.85
Array-based genomic resequencing of human leukemia. Oncogene (2010) 3.77
Generalized-ensemble algorithms for molecular simulations of biopolymers. Biopolymers (2001) 3.69
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med (1997) 3.63
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS (1999) 3.57
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44
Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol (2001) 3.39
Mini-laparoscopic appendectomy using a needle loop retractor offers optimal cosmetic results. Surg Endosc (2004) 3.38
Role of nucleotide sequences of loxP spacer region in Cre-mediated recombination. Gene (1998) 3.31
The mammalian sodium channel BNC1 is required for normal touch sensation. Nature (2000) 3.30
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol (1998) 3.23
Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development. Science (1998) 3.18
Immunoglobulin G: functional sites. Mol Immunol (1985) 3.12
A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. J Mol Biol (1997) 2.95
Cerebral ventriculitis associated with Achromobacter xylosoxidans. J Clin Pathol (1978) 2.86
Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res (1995) 2.79
Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 2.78
Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol (1999) 2.77
Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. Nucleic Acids Res (1990) 2.76
Recurrent subarachnoid hemorrhage from untreated ruptured vertebrobasilar dissecting aneurysms. Neurosurgery (1995) 2.71
gp120: Biologic aspects of structural features. Annu Rev Immunol (2001) 2.70
Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol (2000) 2.67
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity (1999) 2.67
Mapping the prion protein using recombinant antibodies. J Virol (1998) 2.64
Primary structure of poliovirus defective-interfering particle genomes and possible generation mechanisms of the particles. J Mol Biol (1986) 2.63
Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci (2001) 2.60
Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci U S A (1991) 2.60
DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother (1995) 2.57
Occurrence of N-nonsubstituted glucosamine residues in peptidoglycan of lysozyme-resistant cell walls from Bacillus cereus. J Biol Chem (1972) 2.45
HIV-1 antibody--debris or virion? Nat Med (1997) 2.44
Charomids: cosmid vectors for efficient cloning and mapping of large or small restriction fragments. Proc Natl Acad Sci U S A (1986) 2.42
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol (1993) 2.42
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother (1996) 2.42
Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens (2000) 2.35
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
Glia-synapse interaction through Ca2+-permeable AMPA receptors in Bergmann glia. Science (2001) 2.29
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol (1998) 2.28
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
The Saccharomyces cerevisiae genes (CMP1 and CMP2) encoding calmodulin-binding proteins homologous to the catalytic subunit of mammalian protein phosphatase 2B. Mol Gen Genet (1991) 2.23
Familial insertional translocation of a portion of 3q into 11q resulting in duplication and deletion of region 3q22.1 leads to q24 in different offspring. Am J Med Genet (1981) 2.23
Structure and gene organization in the transformed Hind III-G fragment of Ad12. Cell (1980) 2.22
Influence of methylprednisolone on cytokine balance during cardiac surgery. Crit Care Med (1999) 2.21
Smoking prevalence and attitudes toward smoking among Japanese physicians. JAMA (2001) 2.19
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A (1990) 2.12
Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis. Gene (1990) 2.12
Molecular cloning and functional characterization of a new Cap'n' collar family transcription factor Nrf3. J Biol Chem (1999) 2.09
Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Science (1997) 2.06
Role of transforming growth factor-beta in long-term synaptic facilitation in Aplysia. Science (1997) 2.05
Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut (2005) 2.03
Transgenesis by adenovirus-mediated gene transfer into mouse zona-free eggs. Nat Biotechnol (1996) 2.03
Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci U S A (1993) 2.01
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis (2010) 1.98
Scanning of guanine-guanine mismatches in DNA by synthetic ligands using surface plasmon resonance. Nat Biotechnol (2001) 1.98
A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol (1994) 1.97
Electric dipole tracing in the brain by means of the boundary element method and its accuracy. IEEE Trans Biomed Eng (1987) 1.96
Culture of human leukemia cells. Cancer (1966) 1.94
Elastofibroma in Okinawa. A clinicopathologic study of 170 cases. Cancer (1982) 1.94
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A (1994) 1.93
Expression of processed core protein of hepatitis C virus in mammalian cells. J Virol (1991) 1.91
Intrafamilial transmission of hepatitis C virus. Lancet (1989) 1.90
CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol (1995) 1.90
The subcellular localization of SF2/ASF is regulated by direct interaction with SR protein kinases (SRPKs). J Biol Chem (1999) 1.90
Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J Virol (1985) 1.88
Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses (1996) 1.87
Developmental stage- and spermatogenic cycle-specific expression of transcription factor GATA-1 in mouse Sertoli cells. Development (1994) 1.87
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol (1998) 1.87
Characteristics of adherence of enteroaggregative Escherichia coli to human and animal mucosa. Infect Immun (1991) 1.86
Factors associated with operative risk in mitral valve replacement. Am J Cardiol (1969) 1.85
Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest (1995) 1.85
Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses (1997) 1.84
Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors. J Gen Virol (1997) 1.82
Assessment of impulsivity and the development of self-control in students with attention deficit hyperactivity disorder. J Appl Behav Anal (2001) 1.81